Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

@article{Keizer2010ClinicalPO,
  title={Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies},
  author={Ron J. Keizer and Alwin D. R. Huitema and Jan H. M. Schellens and Jos H. Beijnen},
  journal={Clinical Pharmacokinetics},
  year={2010},
  volume={49},
  pages={493-507}
}
Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity. Their pharmacokinetic properties differ markedly from those of non-antibody-type drugs, and these properties can have important clinical implications. mAbs are administered intravenously, intramuscularly or subcutaneously. Oral administration is precluded by the molecular size, hydrophilicity and gastric degradation of mAbs. Distribution… Expand
Pharmacokinetic characteristics of therapeutic antibodies
  • J. Wohlrab
  • Biology, Medicine
  • Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2015
TLDR
Therapeutic antibodies behave differently in terms of absorption, distribution and elimination compared to conventional drugs, and pharmacokinetic conditions can be optimized by coadministration of, for example, methotrexate. Expand
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
TLDR
There is a clear need for more complex models to improve understanding of pharmacokinetic processes and pharmacodynamic interactions of mAbs with the immune system. Expand
The pharmacology and therapeutic applications of monoclonal antibodies
TLDR
Modifications to decrease the immunogenicity and increase the efficacy are described, with examples of optimizing their pharmacokinetic properties and enabling oral bioavailability. Expand
Pharmacokinetics interactions of monoclonal antibodies.
TLDR
The present review will provide an overview on the pharmacokinetics properties of mAbs as related to the most relevant examples of m Abs-small molecule drug interaction. Expand
Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
TLDR
A quantitative overview of the occurrence of assessment and detection of the main covariates associated with monoclonal antibody pharmacokinetics is proposed by comprehensively examining all population pharmacokinetic studies of monoconal antibodies in humans. Expand
Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies
TLDR
Fluctuating or plateau phases in pharmacokinetic profiles of mAbs are a consequence of multiple simultaneously occurring recirculatory as well as adsorption/desorption processes rather than only slow, continuous elimination. Expand
Modeling Approaches to Characterize the Disposition of Monoclonal Antibodies
TLDR
A new scaling approach for anatomical and physiological parameters in PBPK models is derived that translates the inter-individual variability into the design of mechanistic covariate models with direct link to classical compartment models, specially useful for PK population analysis during clinical development. Expand
Assessments of antibody biodistribution
TLDR
Key determinants of mAb disposition, methods for assessing antibody exposure and protein binding, and model‐based approaches that may be utilized to predict mAb pharmacokinetics are summarized. Expand
Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review.
TLDR
For both classes of mAb with anti-inflammatory and antitumor effects, dose-guided optimization based on the measurement of serum concentrations in individual patients could be the next step for a personalized and targeted mAb therapy. Expand
Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens?
  • J. Azanza, B. Sádaba, A. Gómez-Guíu
  • Medicine
  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2015
TLDR
The development of a new formulation containing hyaluronidase allows a subcutaneous route of administration to be used, and has allowed testing the feasibility of administering a fixed dose, with no individual dose adjustments based on weight or body surface. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 143 REFERENCES
Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins
TLDR
The binding of mAbs to their target antigen explains part of their nonlinear PK and PD properties and the interindividual variability in their dose–response relationships must be studied by PK–PD modelling. Expand
Antibody pharmacokinetics and pharmacodynamics.
TLDR
The U.S. Food and Drug administration has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.) which are associated with several interesting pharmacokinetic characteristics. Expand
Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen.
TLDR
The pharmacokinetics and pharmacodynamics of an experimental therapeutic CD3 antibody, CLB-T3/4.A (murine IgA), given as a rejection treatment to renal transplant patients were to a great extent determined by antibody-induced changes in antigen in peripheral blood. Expand
Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients
TLDR
A robust population pharmacokinetic model was developed and evaluated for sibrotuzumab, which identified a possible need to consider body weight when designing dosage regimen for future clinical cancer trials. Expand
Clinical immunotoxicity of therapeutic proteins.
TLDR
There is an urgent need to improve the capacity to anticipate the immunosuppressive risks of novel therapeutic proteins and this could be achieved by the development of clinical immunotoxicology. Expand
The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
TLDR
The pharmacology of therapeutic monoclonal antibodies is complex and dependant on both the structure of the antibody and the physiological system that it targets, and pharmacokinetic and pharmacodynamic modeling often plays a larger role during the development of therapeutic mAbs than for small molecules. Expand
Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct
TLDR
The results indicate that the human variable light-chain subgroup IV can be used for the development of humanized or human immunoglobulin molecules potentially useful in both diagnostic and therapeutic applications with TAG-72-positive tumors. Expand
Early development of therapeutic biologics--pharmacokinetics.
  • A. Baumann
  • Biology, Medicine
  • Current drug metabolism
  • 2006
TLDR
Bioanalytical method development and validation is a prerequisite not exclusively for pharmacokinetic studies but for the whole pre-clinical and clinical development of biologics, due to their unique properties. Expand
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
TLDR
This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart, which may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans. Expand
Antibodies as Carrier Proteins
TLDR
This mini-review attempts to delineate the causal relation between the factors influencing antibody binding and the circulatory life of a therapeutic agent, be it a small drug or a macromolecule. Expand
...
1
2
3
4
5
...